EuroNanoMed I call statistics
During the period 2009-2011, the ERA-NET EuroNanoMed I has successfully organized 3 joint calls for proposals. EuroNanoMed I funded 24 transnational research projects on nanomedicine involving 126 partners from 19 countries/regions, with € 25 million funding from the EuroNanoMed I partners and a further € 21 million funding from the research partners participating in the funded projects. This represents an important leverage effect for EuroNanoMed I:
x 18.8 if the funding of research projects from the EuroNanoMed I partners (€ 1 in Framework programme funding results in € 18.8 euro funding implemented by ERA-NETs) is taken into account; or
x 34.6 if we include the funding from the research partners participating in the funded projects.
Country of origin of the applicants
Altogether, 502 partners from more than 17 countries participated in these calls, in a total of 98 submitted projects. The number of applicants per country is presented in figure 1. As presented here, the number of applicants has grown in between 2009 and 2011, from 24 to 41 submitted proposals at each call.
Figure 1: Number of applicants per country for each EuroNanoMed I joint call for proposals. ‘Non participating country’ refers to applicants that belonged to countries where no funding organization participated in the joint transnational call.
Success rates
The table below recapitulates the outcomes of each EuroNanoMed I call:
|
JTC-2009 |
JTC-2010 |
JTC-2011 |
|
| Number of submitted proposals |
24 |
33 |
41 |
| Number of funded projects |
8 |
8 |
8 |
| Total costs of funded projects (M€) |
16.9 |
15.9 |
13.3 |
| Allocated funding (M€) |
9 |
8 |
8 |
| Success rate (%) |
33 |
24 |
20 |
Participation of research organizations in translational projects in Nanomedecine
As EuroNanoMed I joint calls for proposals aimed at funding transnational research projects in Nanomedicine, each funded consortium had to include teams from at least 2 of the following categories: academia, industry, clinic/public health. The distribution between these three categories among funded consortia is outlined in Figure 2. Noteworthy, 62% of the funded projects included partners from all three categories, indicating the high added value of these collaborations in nanomedicine translational research.
Figure 2: Type of research organizations funded through the three EuroNanoMed I joint calls for proposals.
Scientific / technological areas covered by funded projects
The three EuroNanoMed I joint calls for proposals were open to proposals covering at least one of the three priority topics of the European Technology Platform Nanomedecine: Targeted delivery systems, Diagnostics, Regenerative medicine. The coverage of these three scientific / technological areas among funded projects is presented in figure 3.
Figure 3: Distribution of scientific / technological areas covered by funded projects in each of the three EuroNanoMed I joiny calls.
EuroNanoMed III is funded under the ERA-NET Cofund scheme of the Horizon 2020 Research and Innovation Framework Programme of the European Commission, Research Directorate-General, Grant Agreement No. 723770
Instituto de Salud Carlos III (ISCIII)
Monforte de Lemos 5, 28029 – Madrid, Spain
era@isciii.esCoordinator
Ignacio Baananteibaanante@isciii.es
+34 9182 22576Instituto de Salud Carlos III (ISCIII)
Monforte de Lemos 5, 28029 – Madrid, Spainma.valencia@isciii.es+ 34 91 822 2227VDI Technologiezentrum GmbH
Dr. Olaf Rotthausrotthaus@vdi.de+49 211 6214 233Ⓒ All rights reserved EuroNanoMed III, 2018
